Respected were the beneficial effects obtained with free peptides or peptides with different carriers
Side Effects, Long-Term Risks, FDA Concerns, and Unknowns Short Answer: DSIP safety is not well established, particularly for long-term, non-medical, or compounded peptide use
Institutional Requirements Academic and commercial research facilities maintain strict protocols
Unlike a stimulant, it does not produce a same-day effect the published trials titrated the dose upward over weeks and measured their primary weight endpoints at 26 weeks (Phase 2) and 68 weeks (Phase 3)
The body builds that supply slowly
No lethal dose has been established in animal studies, even at dosages many orders of magnitude higher than those used in therapeutic research